Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

Jul 01, 2024

Pharmaceuticals
R&D

CHMP Recommends EU approval of Chugai’s PiaSky for People with PNH

TOKYO, July 1, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a Media Release regarding the Chugai originated pH-dependent binding humanized anti-complement (C5) monoclonal antibody PiaSky^® (generic name: crovalimab (genetical recombination)). The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended to approve PiaSky for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), for use in adults and adolescents (12 years of age or older with a weight of 40 kg) who are either new to, or have been previously treated with C5 inhibitors.

Please refer to the link below for details of the Roche’s Media Release:

CHMP recommends EU approval of Roche’s PiaSky for people with PNH, a rare, life-threatening blood condition
https://www.roche.com/media/releases/med-cor-2024-06-28

[PDF 265KB]

Back